Pediatric Asthma Management

Controller Therapies

For children with persistent asthma, low-dose inhaled corticosteroids (ICS) are the preferred first-line controller therapy, with specific dosing determined by age, severity, and the ICS molecule selected, as recommended by the American Academy of Pediatrics 1
Low-dose ICS is the preferred therapy for mild persistent asthma in children 5 years and older, delivered via metered-dose inhaler with spacer, dry powder inhaler, or nebulizer, according to the American College of Allergy, Asthma, and Immunology 1
Alternative options for mild persistent asthma include leukotriene receptor antagonists (montelukast), cromolyn, or nedocromil, though these are less effective than ICS, as stated by the National Asthma Education and Prevention Program 1

Acute Asthma Treatment

Nebulized salbutamol 5 mg or terbutaline 10 mg via oxygen-driven nebulizer is recommended for immediate treatment of acute severe asthma, with half doses in very young children, as suggested by the British Thoracic Society 2
Oral prednisolone 1-2 mg/kg body weight daily (maximum 40 mg) for 1-5 days is recommended for acute severe asthma, with no tapering needed, according to the American Academy of Pediatrics 2, 3

Dosing Considerations

Nebulized bronchodilator dosing: salbutamol 2.5 mg for children up to age 2 years, 5 mg for children over age 2 years, as recommended by the European Respiratory Society 4
Intravenous aminophylline 5 mg/kg over 20 minutes, followed by maintenance infusion of 1 mg/kg/hour, is recommended for life-threatening features of asthma in children, as stated by the American College of Chest Physicians 2, 5, 6

Monitoring and Adjustment

Step-Up Criteria: add LABA to low-dose ICS, or increase ICS to medium-dose range, or add leukotriene receptor antagonist to ICS, if control is not achieved within 4-6 weeks, as recommended by the National Asthma Education and Prevention Program 1
Step-Down Criteria: attempt after benefits sustained for 2-4 months, and reassess inhaler technique before stepping down, as suggested by the American Academy of Allergy, Asthma, and Immunology 1, 2

Critical Pitfalls to Avoid

Never omit the aminophylline loading dose without confirming theophylline use history, as giving a loading dose to a child already on oral theophyllines can cause toxicity, as warned by the American College of Medical Toxicology 2, 5, 6
Verify proper inhaler technique at every visit, as poor technique is a common cause of treatment failure, as emphasized by the American Thoracic Society 2, 1

Corticosteroid Treatment for Pediatric Asthma Exacerbation

Dosing Guidelines

The British Thoracic Society recommends a maximum dose of 40 mg of prednisolone for children, regardless of weight, to balance efficacy with minimizing corticosteroid side effects in the pediatric population 7, 8
For a child with asthma exacerbation, the American Academy of Pediatrics suggests calculating the weight-based dose of 1-2 mg/kg body weight orally, but not exceeding the maximum dose of 40 mg 7, 8
The final dose for a 41 kg child would be 40 mg prednisolone orally, as the maximum allowed dose takes precedence over the weight-based calculation 7, 8

Treatment Duration and Monitoring

The British Thoracic Society guidelines recommend continuing treatment for 1-5 days until control is established, and reassessing daily until 2 days after control is established 9
The American Academy of Pediatrics suggests assessing severity objectively using peak expiratory flow measurements or validated clinical scores, and continuing treatment until symptoms resolve and peak flow reaches 80% of predicted or personal best 7, 8
Arranging follow-up within 1 week to ensure adequate recovery is also recommended 7, 8

Route of Administration

Intravenous hydrocortisone (200 mg every 6 hours) is reserved for children too ill to take oral medications or with life-threatening features 7, 8

Management of Persistent Asthma in School‑Age Children (≈7 years)

Developmental Impact of Asthma Control

Proper asthma control during the critical 5‑11 year developmental window helps prevent long‑term impairment of lung growth. 10

Controller Therapy and Delivery Device

For children in this age group, a metered‑dose inhaler (MDI) used with a large‑volume spacer is the preferred delivery device because most 7‑year‑olds cannot achieve adequate coordination with an unmodified MDI. 11

Treatment Goals

Aim for minimal daytime symptoms and no nighttime awakenings. 11
Aim for zero missed school days. 11
Aim for full participation in activities and sports without limitation. 10

Written Asthma Action Plan & Education

The action plan should be symptom‑based and developed with direct involvement of the child, addressing the child’s concerns, preferences, and school schedule. 10
Include a school medication administration plan to ensure the child has timely access to controller and rescue medication at school. 10

Rescue Medication & Acute Home Management

For acute worsening at home, repeat albuterol dosing every 2–4 hours; lack of response or early deterioration should prompt immediate medical assessment. 11
Routine home use of nebulizers should be avoided; an MDI with a large‑volume spacer provides equivalent efficacy, is less costly, and reduces unnecessary nebulizer use. 11

Exercise‑Induced Bronchoconstriction (EIB)

Pretreat with albuterol 15 minutes before exercise to prevent EIB. 10
As an alternative, a daily leukotriene receptor antagonist can be used as part of the controller regimen for children who experience exercise‑related symptoms. 10
Encourage regular physical activity; treat exercise‑related bronchoconstriction rather than restricting activity. 10
Implement a warm‑up period before vigorous exercise to lessen the severity of EIB. 10

Monitoring and Follow‑Up

At each visit, document days of school missed, frequency of daytime and nighttime symptoms, frequency of rescue medication use, and any activity limitation. 11
Record height and weight velocities to monitor for potential growth suppression when high‑dose inhaled corticosteroids (>400 µg/day) are used; low‑dose regimens have minimal impact compared with the growth‑delaying effect of uncontrolled asthma itself. 11
Verify inhaler technique at every visit; improper technique is the most common cause of apparent treatment failure. 11
Never use an unmodified MDI without a spacer because lung deposition is poor and systemic absorption increases. 11

Special Considerations for the Age Group

Ongoing monitoring for disease progression and potential loss of lung growth is essential; stepping up therapy may be required as the child grows to maintain control. 10
Schedule regular follow‑up every 3–6 months to reassess control, adjust therapy, and ensure continued adequate management. 10

Corticosteroid Management for Acute Bronchospasm in Children

Preferred Route of Administration

Oral prednisolone (1–2 mg/kg, maximum 40 mg) is the preferred initial therapy for children who can tolerate oral medication, providing efficacy comparable to intravenous methylprednisolone while avoiding IV‑related risks. 12

Indications for Intravenous Administration

Intravenous methylprednisolone should be reserved for children with life‑threatening bronchospasm who cannot take oral medication, such as those with imminent respiratory failure, progressive respiratory fatigue, or inability to swallow. 12

Maximum Daily Doses

Do not exceed a total daily dose of 60 mg when using intravenous methylprednisolone or 40 mg when using oral prednisolone, regardless of weight‑based calculations. 12

Dosing for Relative Adrenal Insufficiency

In severe asthma exacerbations with relative adrenal insufficiency, an adequate corticosteroid dose of 2–3 mg/kg is recommended to ensure sufficient adrenal support. 13

Timing of Corticosteroid Administration

Corticosteroids must be administered immediately together with bronchodilator therapy; delaying steroid administration until after bronchodilator response provides no benefit. 14

Mandatory Concomitant Therapy

Always combine corticosteroid treatment with nebulized salbutamol (5 mg, or 2.5 mg for children under 2 years) and high‑flow supplemental oxygen delivered via face mask. 12